Experimental TYK2/JAK1 inhibitor shows promise against plaque psoriasis
PF-06700841, a TYK2/JAK1* inhibitor under investigation, shows good efficacy against moderate-to-severe plaque psoriasis and carries a well-tolerable safety profile, according to new results of a phase IIa trial.